9 completed. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 2 | Completed 2 |
Follow Vyxeos: new trials by email Literature Review of Vyxeos trials Research Report on Vyxeos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine - Acute Myeloid Leukemia, Myeloid Neoplasm | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2020-05-27 | 2026-06-29 |
| Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML CPX-351, Daunorubicin, Cytarabine - MDS, AML | Phase 2 | Completed | GWT-TUD GmbH | 150 | 2019-08-19 | 2026-09-10 |
| Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Palcociclib, CPX-351 - Acute Myeloid Leukemia, AML | Phase 1 / Phase 2 | Completed | Sudipto Mukherjee, MD, PhD, MPH | 35 | 2019-06-06 | 2025-05-31 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2018-11-07 | 2026-07-24 |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia CPX-351 - Lymphoid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 11 | 2018-10-11 | 2024-12-12 |
| Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Cytarabine, Decitabine, Idarubicin - Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | University of Nebraska | 75 | 2017-07-07 | 2026-03-10 |
| Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine Phosphate - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 38 | 2016-05-02 | 2023-09-08 |
| CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Completed | M.D. Anderson Cancer Center | 56 | 2015-05-04 | 2026-06-04 |
Leukemia, Myeloid, Acute (5) · Burkitt Lymphoma (1) · Leukemia, Lymphoid (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
M.D. Anderson Cancer Center (2) · Children's Oncology Group (1) · Fred Hutchinson Cancer Center (1) · GWT-TUD GmbH (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Roswell Park Cancer Institute (1) · Sudipto Mukherjee, MD, PhD, MPH (1) · University of Nebraska (1)
United States (8) · Austria (1) · Canada (1) · Germany (1)
Bijal Shah, M.D. (1) · Eunice Wang, MD (1) · Ghayas Issa (1) · Roland Walter (1) · Sudipto Mukherjee, MD, PhD (1) · Todd M Cooper (1) · Uwe Platzbecker, Prof. (1) · Vijaya R Bhatt, MD (1) · Yesid Alvarado-Valero, MD (1)
PMID 32401633, PMID 35450817, PMID 38000343, PMID 40298352, PMID 42835577
P30CA036727 (1), U10CA180886 (1)